Skip to main content
SpringerLink
Log in

Pulmonary Arterial Hypertension

  • Chapter
  • First Online:
Arterial Disorders

Abstract

Pulmonary arterial hypertension (PAH) is a debilitating disease characterized by progressive adverse remodeling of the resistance pulmonary arteries, ultimately leading to right ventricular (RV) failure and death. It is defined by increases in pulmonary arterial pressures (PAP), pulmonary vascular resistance (PVR), and ultimately, right ventricular failure. The field of PAH has made remarkable progress in the last two decades with understanding in the pathogenesis and improvements in therapeutic and prognostic tools. In this chapter, we will review the definition, pathogenesis, epidemiology, clinical presentation, management, and prognostication of PAH in the current era.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Farber HW, Loscalzo J (2004) Pulmonary arterial hypertension. N Engl J Med 351:1655–1665

    Article  CAS  PubMed  Google Scholar 

  2. Rich S, Pogoriler J, Husain AN et al (2010) Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest 138:1234–1239

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Ryan JJ, Archer SL (2014) The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res 115:176–188

    Article  CAS  PubMed  Google Scholar 

  4. Archer SL, Fang YH, Ryan JJ, Piao L (2013) Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ 3:144–152

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Piao L, Fang YH, Parikh KS et al (2012) GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation 126:2859–2869

    Article  CAS  PubMed  Google Scholar 

  6. Tedford RJ, Mudd JO, Girgis RE et al (2013) Right ventricular dysfunction in systemic sclerosis associated pulmonary arterial hypertension. Circ Heart Fail 6:953–963

    Article  CAS  PubMed  Google Scholar 

  7. Drake JI, Gomez-Arroyo J, Dumur CI et al (2013) Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. Physiol Genomics 45:449–461

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. van de Veerdonk MC, Kind T, Marcus JT et al (2011) Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 58:2511–2519

    Article  PubMed  Google Scholar 

  9. McLaughlin VV, Archer SL, Badesch DB et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53:1573–1619

    Article  PubMed  Google Scholar 

  10. Best DH, Austin ED, Chung WK, Elliott CG (2014) Genetics of pulmonary hypertension. Curr Opin Cardiol 29:520–527

    Google Scholar 

  11. Rich S, Dantzker R, Ayres S et al (1987) Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107:216–223

    Article  CAS  PubMed  Google Scholar 

  12. Frost AE, Badesch DB, Barst RJ et al (2011) The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest 139:128–137

    Article  PubMed  Google Scholar 

  13. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M (2007) A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J 30:1103–1110

    Article  CAS  PubMed  Google Scholar 

  14. Humbert M, Sitbon O, Chaouat A et al (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173:1023–1030

    Article  PubMed  Google Scholar 

  15. Badesch DB, Raskob GE, Elliott CG et al (2010) Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest 137:376–387

    Article  PubMed  Google Scholar 

  16. McGoon MD, Benza RL, Escribano-Subias P et al (2013) Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 62:D51–D59

    Article  PubMed  Google Scholar 

  17. Ling Y, Johnson MK, Kiely DG et al (2012) Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 186:790–796

    Article  PubMed  Google Scholar 

  18. Brown LM, Chen H, Halpern S et al (2011) Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest 140:19–26

    Article  PubMed Central  PubMed  Google Scholar 

  19. Fisher MR, Forfia PR, Chamera E et al (2009) Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 179:615–621

    Article  PubMed Central  PubMed  Google Scholar 

  20. Rich JD, Shah SJ, Swamy RS et al (2011) Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 139:988–993

    Article  PubMed  Google Scholar 

  21. Chandra S, Shah SJ, Thenappan T et al (2010) Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant 29:181–187

    Article  PubMed  Google Scholar 

  22. Atwood CW Jr, McCrory D, Garcia JG et al (2004) Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. Chest 126:72S–77S

    Article  PubMed  Google Scholar 

  23. Hoeper MM, Mayer E, Simonneau G, Rubin LJ (2006) Chronic thromboembolic pulmonary hypertension. Circulation 113:2011–2020

    Article  PubMed  Google Scholar 

  24. Halpern SD, Taichman DB (2009) Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left-ventricular end-diastolic pressure. Chest 136:37–43

    Article  PubMed  Google Scholar 

  25. Hoeper M, Maier R, Tongers J et al (1999) Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 160:535–541

    Article  CAS  PubMed  Google Scholar 

  26. Freed BH, Gomberg-Maitland M, Chandra S et al (2012) Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson 14:11

    Article  PubMed Central  PubMed  Google Scholar 

  27. Caldeira D, Loureiro MJ, Costa J et al (2014) Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis. Can J Cardiol 30:879–887

    Article  PubMed  Google Scholar 

  28. Rich S, Kaufman E, Levy P (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81

    Article  CAS  PubMed  Google Scholar 

  29. Sitbon O, Humbert M, Jais X et al (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105–3111

    Article  CAS  PubMed  Google Scholar 

  30. Galie N, Ghofrani HA, Torbicki A et al (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148–2157

    Article  CAS  PubMed  Google Scholar 

  31. Galie N, Brundage BH, Ghofrani HA et al (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894–2903

    Article  CAS  PubMed  Google Scholar 

  32. Oudiz RJ, Brundage BH, Galie N et al (2012) Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol 60:768–774

    Article  CAS  PubMed  Google Scholar 

  33. Rubin L, Badesch D, Barst R et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903

    Article  CAS  PubMed  Google Scholar 

  34. Galie N, Olschewski H, Oudiz RJ et al (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117:3010–3019

    Article  CAS  PubMed  Google Scholar 

  35. Pulido T, Adzerikho I, Channick RN et al (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809–818

    Article  CAS  PubMed  Google Scholar 

  36. Ghofrani HA, Galie N, Grimminger F et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330–340

    Article  CAS  PubMed  Google Scholar 

  37. Barst R, Rubin L, Long W et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334:296–301

    Article  CAS  PubMed  Google Scholar 

  38. McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106:1477–1482

    Article  CAS  PubMed  Google Scholar 

  39. Sitbon O, Humbert M, Nunes H et al (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40:780–788

    Article  CAS  PubMed  Google Scholar 

  40. Barst RJ, Galie N, Naeije R et al (2006) Long-term outcome in pulmonary arterial hypertension patients treated with treprostinil. Eur Respir J 28:1195–1203

    Article  CAS  PubMed  Google Scholar 

  41. Lang I, Gomez-Sanchez M, Kneussl M et al (2006) Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 129:1636–1643

    Article  CAS  PubMed  Google Scholar 

  42. Olschewski H, Simonneau G, Galie N et al (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329

    Article  CAS  PubMed  Google Scholar 

  43. McLaughlin VV, Benza RL, Rubin LJ et al (2010) Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 55:1915–1922

    Article  CAS  PubMed  Google Scholar 

  44. Jing ZC, Parikh K, Pulido T et al (2013) Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 127:624–633

    Article  CAS  PubMed  Google Scholar 

  45. Tapson VF, Jing ZC, Xu KF et al (2013) Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 144:952–958

    Article  CAS  PubMed  Google Scholar 

  46. Simonneau G, Rubin LJ, Galie N et al (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149:521–530

    Article  PubMed  Google Scholar 

  47. Galie N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34:1219–1263

    Article  CAS  PubMed  Google Scholar 

  48. D'Alonzo GE, Barst RJ, Ayres SM et al (1991) Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115:343–349

    Article  PubMed  Google Scholar 

  49. Thenappan T, Shah SJ, Rich S et al (2010) Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 35:1079–1087

    Article  CAS  PubMed  Google Scholar 

  50. Humbert M, Sitbon O, Chaouat A et al (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122:156–163

    Article  PubMed  Google Scholar 

  51. Humbert M, Sitbon O, Yaici A et al (2010) Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 36:549–555

    Article  CAS  PubMed  Google Scholar 

  52. Benza RL, Gomberg-Maitland M, Miller DP et al (2012) The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 141:354–362

    Article  PubMed  Google Scholar 

  53. Benza RL, Miller DP, Gomberg-Maitland M et al (2010) Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122:164–172

    Article  PubMed  Google Scholar 

  54. Macchia A, Marchioli R, Tognoni G et al (2010) Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J 159:245–257

    Article  CAS  PubMed  Google Scholar 

  55. Galie N, Manes A, Negro L et al (2009) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30:394–403

    Article  PubMed Central  PubMed  Google Scholar 

  56. Shapiro S, Traiger GL, Turner M et al (2012) Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest 141:363–373

    Article  PubMed  Google Scholar 

  57. Frost AE, Badesch DB, Miller DP et al (2013) Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest 144:1521–1529

    Article  PubMed  Google Scholar 

  58. Macchia A, Marchioli R, Marfisi R et al (2007) A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 153:1037–1047

    Article  PubMed  Google Scholar 

  59. Shah S, Thenappan T, Rich S et al (2009) Value of exercise treadmill testing in the risk stratification of patients with pulmonary hypertension. Circ Heart Fail 2:278–286

    Article  PubMed  Google Scholar 

  60. Wensel R, Opitz C, Anker S et al (2002) Assessment of survival in patients with primary pulmonary hypertension. Circulation 106:319–324

    Article  PubMed  Google Scholar 

  61. Forfia PR, Fisher MR, Mathai SC et al (2006) Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 174:1034–1041

    Article  PubMed  Google Scholar 

  62. Hinderliter A, Willis PW IV, Long W et al (1999) Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. Am J Cardiol 84:481–484

    Article  CAS  PubMed  Google Scholar 

  63. Raymond R, Hinderliter A, Willis P et al (2002) Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 39:1214–1219

    Article  PubMed  Google Scholar 

  64. Fenstad ER, Le RJ, Sinak LJ et al (2013) Pericardial effusions in pulmonary arterial hypertension: characteristics, prognosis, and role of drainage. Chest 144:1530–1538

    Article  PubMed  Google Scholar 

  65. van Wolferen SA, Marcus JT, Boonstra A et al (2007) Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 28:1250–1257

    Article  PubMed  Google Scholar 

  66. Mahapatra S, Nishimura RA, Sorajja P et al (2006) Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 47:799–803

    Article  PubMed  Google Scholar 

  67. Agarwal R, Gomberg-Maitland M (2012) Prognostication in pulmonary arterial hypertension. Heart Fail Clin 8:373–383

    Article  PubMed  Google Scholar 

  68. McLaughlin VV (2006) Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest 36(Suppl 3):10–15

    Article  CAS  PubMed  Google Scholar 

  69. McLaughlin VV, Sitbon O, Badesch DB et al (2005) Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25:244–249

    Article  CAS  PubMed  Google Scholar 

  70. Thenappan T, Glassner C, Gomberg-Maitland M (2012) Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest 141:642–650

    Article  PubMed  Google Scholar 

  71. Cogswell R, Kobashigawa E, McGlothlin D et al (2012) Validation of the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) pulmonary hypertension prediction model in a unique population and utility in the prediction of long-term survival. J Heart Lung Transplant 31:1165–1170

    Article  PubMed  Google Scholar 

  72. Simonneau G, Gatzoulis MA, Adatia I (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34–D41

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular, University of Minnesota, Medical School, 420 Delaware street SE, MMC 508, Minneapolis, MN, 55455, USA

    Thenappan Thenappan MD & Daniel Duprez MD, PhD

Authors
  1. Thenappan Thenappan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Duprez MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Duprez MD, PhD .

Editor information

Editors and Affiliations

  1. American University of Beirut Medical Center, Beirut, Lebanon

    Adel Berbari

  2. University of Milano Bicocca IRCCS Istituto Auxologico Italiano, Milan, Italy

    Giuseppe Mancia

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Thenappan, T., Duprez, D. (2015). Pulmonary Arterial Hypertension. In: Berbari, A., Mancia, G. (eds) Arterial Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-14556-3_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-14556-3_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-14555-6

  • Online ISBN: 978-3-319-14556-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation